NFE2L2 and ovarian carcinoma: Interestingly, cisplatin-resistant ovarian cancer cells (A2780CP, COC1/DDP, PEO4) increase NRF2 levels and reduce SLC40A1 levels compared with cisplatin-sensitive cells (A2780, COC1, PEO1).